Open original FDA record ↗Recall record
- FDA identifier
- Z-1800-2020
- Company in FDA record
- Bio-Rad Labs
- FDA record creation date
- Apr 24, 2020
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
An elevated lot-to-lot bias was observed for Autoimmune EIA Anti-Tissue Transglutaminase (tTG) IgA when compared to a previous lot of product. The observed elevated bias between these two lots is largely due to samples with higher levels of antibodies. With the cut-off for the assay being 15 U/mL, the clinical classifications for most samples would remain unchanged.
Source facts
- Action
- On April 3, 2019, a Field Action Letter with response form was sent to U.S. Customers via Fed Ex courier while subsidiaries were notified via email. Customers were instructed to immediately discontinue further use of, and dispose of, any unused product according to local waste management procedures. Customers were requested to complete the attached customer response form as an acknowledgement with information including: account name, customer account number, contact name and title, address, and telephone number. Customers were instructed to check off the statement acknowledging awareness of the field action and that they had proceeded according to instructions issued by Bio-Rad. Completed forms were to be returned to RA_CID@bio-rad.com. Customers were instructed to contact their local Bio-Rad Technical Support with any questions regarding the Field Action Notification.
- Initiated
- 2019-04-03
- Root cause
- Under Investigation by firm
- Distribution
- US Nationwide distribution including the states of AZ, NY, LA, FL, CA, TX, IA, MS, UT, and IL.
- Recall number
- Z-1800-2020
- Recall status
- Completed
- CDRH record ID
- 180028
- FDA record created
- 2020-04-24
- Recall event number
- 85074